A Phase 2 Randomized, Controlled Study With a Phase 1 Safety Cohort Testing ALD-401 Derived From Autologous Bone Marrow Delivered Via Intracarotid Infusion in Subjects With Ischemic Stroke Using Blinded Assessments
Latest Information Update: 07 Nov 2021
At a glance
- Drugs ALD 401 (Primary)
- Indications Stroke
- Focus Adverse reactions; Therapeutic Use
- Acronyms RECOVER-Stroke
- Sponsors Aldagen
- 21 Apr 2016 Results of an exploratory analysis (n=11) presented at the 68th Annual Meeting of the American Academy of Neurology
- 19 Feb 2016 Results of exploratory analysis (n=11) presented at the 41st International Stroke Conference
- 05 May 2014 Primary endpoint 'Rankin-scale' has not been met, according to a Cytomedix media release.